Exhibit 10.8


 





 


PRIVATE AND CONFIDENTIAL


 


To the attention of:


Mr. Per Regnarsson


Mr. Abhishek
Bawa


ClimateRock


50 Sloane Avenue,


London, SW3 3DD


United Kingdom


 


London, 11 July 2022


 


Dear Per and Abhishek,


 


Pursuant to our recent conversations,
we are pleased to confirm the arrangements under which Alantra Corporate Finance, S.A.U. (“ALANTRA”, “we”
or “us”) is engaged by ClimateRock, a special purpose acquisition company, with corporate domicile at 50 Sloane Avenue,
London, SW3 3DD, United Kingdom (hereinafter, the “Company” or “you”), to act as its financial advisor
for the design, negotiation and execution of potential business combinations between the Company and one or more energy transition companies
(each of those a “Transaction” and all together, the “Transactions”).


 


1. Scope of Services


 


As part of this mandate, ALANTRA
will conduct a complete search of suitable Targets (as defined below) for the Company in the renewable energy sector globally. ALANTRA
will be the exclusive advisor for Transactions in Europe, Latin America and the Middle East. ALANTRA will be non-exclusive advisor for
Transactions in North America, Asia and Africa. For Transactions in North America, Asia and Africa ALANTRA will be the Company’s
M&A advisor, also where Transactions are not introduced by ALANTRA.


 


We will be looking for Targets
in the following sectors: onshore and offshore wind generation, solar PV generation, combined heat and power, concentrated solar power,
hydropower generation, energy storage and hydrogen.


 


If a Target or Targets responds
positively to our approaches, we shall provide you with transaction advisory services, which will include valuations of the Target(s),
evaluations of alternative negotiation strategies, a recommendation of preferred approaches and transaction structures, and the preparation
of any business reviews and other analytical work that may be required. On a more detailed basis, our advisory services (the “Services”)
will include:


 


		(i)	Finding and identifying one or more potential target companies, for the
Company’s business combination (each a, “Target”);



 


		(ii)	Defining procedures concerning
the acquisition process at its different stages, and implementing them on your behalf;



 




     


     


    

 





 


		(iii)	Providing operational assistance
to the Company’s in-house project team in all matters relating to the Transactions;



 


		(iv)	Serving as a key contact to
the seller and its representatives and advisors (in close coordination with the Company’s project team);



 


		(v)	Requesting, gathering and analyzing
information relevant to the Target(s), their markets and the proposed Transactions;



 


		(vi)	Preparing and reviewing a valuation
of the businesses;



 


		(vii)	Advising on the value and terms
of your offer and on appropriate negotiating strategies and deal tactics;



 


		(viii)	Coordinating external advisors
(i.e. accountants, auditors, lawyers and commercial advisors);



 


		(ix)	Performing and coordinating
the due diligence exercise, including reviewing the results of the due diligence undertaken by other professional advisers in the context
of the evaluation of the target company/ies;



 


		(x)	Assisting in the preparation
of internal documentation for the Company regarding the Transactions (e.g. time table, contact log, status updates, investment committee
decision papers, etc.);



 


		(xi)	Reviewing and commenting as
far as relevant in light of the Services on documentation which will be required to be filed with the Securities and Exchange Commission
(“SEC”)



 


		(xii)	Undertaking the day-to-day
management of the Transactions, assisting in the coordination and administration of all external advisers and reporting on progress;
and



 


		(xiii)	Assisting in the negotiation
of binding contractual documentation in conjunction with your legal advisers.



 


ALANTRA’s advice will be
confined to that normally given by a financial adviser in transactions of the nature of the Transactions. We will not be responsible for
giving or obtaining commercial advise or special advice or service in areas which are outside our expertise, such as that normally carried
out by a legal, accountancy, tax or environmental adviser, or where you will (or customarily would) have other advisers involved.


 


In providing the Services, ALANTRA
may assume that all your directors and officers and employees named by you from whom we receive instructions are duly authorized to give
any such instructions and may do anything which is reasonable or necessary either for ALANTRA to perform the Services or to comply with
any applicable laws, rules, regulations, authorizations, consents or practices as may be reasonable or appropriate.


 




    2/10


     


    

 





 


2. Fees


 


Retainer Fee


 


The Company will pay ALANTRA USD
15,000 at signing of this Engagement Letter and a Retainer Fee of USD 20,000 per month that is due and payable on the last day of each
month for a maximum period of five months.


 


Should the aggregated Transaction
value be above USD 400 million, the Retainer Fee will increase up to USD 40,000 per month with the same maximum five-month period for
the payment of any Retainer Fee.


 


The Retainer Fee will no longer be due after termination
of this Engagement Letter. Transaction Success Fee


 


The
mandate could include multiple Transactions and the fees of each will be paid by the Company to ALANTRA on each Transaction
Completion as follows.


 


If a Transaction which is introduced
by ALANTRA or by another institution to which no fees are due by the Company (e.g. an institution acting on behalf of a Target) is Completed
(as defined below) the Company shall pay ALANTRA a remuneration for its Services (“Transaction Success Fee”) in the
form of


 


		a	For the first USD 300,000,000 (THREE HUNDRED MILLION US DOLLARS) of aggregated
value of the Transaction , 1.0% of each Transaction purchase price.



 


		a	For the aggregated value of the Transaction above the first USD 300,000,000 (THREEHUNDRED
MILLION US DOLLARS), 0.5% of each Transaction purchase price.



 


If a Transaction is Completed (as
defined below) in North America, Asia or Africa which is not introduced by ALANTRA and such Transaction requires an introductory, co-advisory
or similar fee due by the Company, the Company shall pay ALANTRA a Transaction Success Fee in the form of:


 


		a	For the first USD 300,000,000 (THREE HUNDRED MILLION US DOLLARS) of aggregated
value of the Transaction, 0.85% of each Transaction purchase price.



 


		a	For the aggregated value of the Transaction above the first USD 300,000,000 (THREE
HUNDRED MILLION US DOLLARS), 0.4% of each Transaction purchase price.



 


Notwithstanding the above, it
is agreed that the Transaction Success Fee will be subject to a minimum of EUR 1,000,000 (ONE MILLION EUROS).


 


The
Transaction purchase price will correspond to the price paid to the sellers of the applicable Target, including cash, debt and
equity funded payments.


 




    3/10


     


    

 





 


Each Transaction Success Fee shall
be payable upon consummation of the applicable Transaction (i.e. when the transaction is closed, following fulfillment, if applicable,
of conditions precedent) regardless of (i) the calendar for the payment of the price, (ii) how the purchase price is funded, (iii) any
deferred payment subsequent to consummation of the Transaction, or (iv) any adjustments to the price of the Transaction subsequent to
consummation (“Completion”).


 


3. Expenses, Invoicing and
Taxes


 


In addition to the fees described
in Section 2 above, the Company will reimburse ALANTRA for all reasonable and documented out-of-pocket expenses incurred in connection
with providing the Services for the Transactions, which will be billed from time-to-time. Generally, these represent travel, accommodation,
document production, telecommunications and courier costs and related matters; provided that (i) no individual expense (or series of related
expenses) in excess of USD 10,000 shall be incurred without prior written approval by the Company and (ii) no expenses may be incurred,
in the aggregate, in excess of USD 50,000 without prior written approval by the Company.


 


The Company will pay its own fees
and expenses and general Transaction related fees and expenses incurred in connection with providing the Services for the Transaction
including without limitation, those related to the Company’s legal counsels and auditors, any due diligence investigations conducted
by third parties commissioned by the Company, the cost of any investor presentations, fees, and printing costs.


 


All amounts payable to ALANTRA
under the terms of this letter agreement shall be paid to ALANTRA free and clear of, and without any deduction or withholding for or on
account of, any current or future taxes, levies, duties, or charges. Without limiting the foregoing, all amounts payable will be exclusive
of value added tax or any other similar taxes (“VAT”). All amounts charged will be invoiced together with VAT, where
appropriate.


 


All amounts payable by the Company
hereunder shall be payable within 15 days of presentation of an invoice by ALANTRA. All invoicing will be in Euros.


 


4. Information, Confidentiality
and Publicity


 


The Company will furnish or cause
to be furnished to ALANTRA such information as we believe appropriate to execute the Transactions and will provide ALANTRA with access
to the officers, directors, employees, auditors, counsels and other representatives of the Company and its affiliates.


 


ALANTRA will rely on the accuracy
and completeness, without independent verification, of any information we receive in connection with this engagement. We will not independently
evaluate or appraise any assets or liabilities that may be involved in this engagement.


 


The Company will be solely responsible
for the content of the information it will furnish to ALANTRA that is used in the course of the Transactions; provided that any information
provided on behalf of a Target shall be to the best of the Company’s knowledge. Consequently, it should not be understood that ALANTRA,
through the elaboration of the documents regarding the Transactions (hereinafter the “Analysis”), guarantees the completeness
or accuracy of the content of such documents.


 




    4/10


     


    

 





 


The criteria used to prepare the
Analysis are based on estimates of future results of the Company and the targets, their businesses and assets and in light of the inherent
uncertainties of any information concerning the future, some of these hypotheses might not materialize as defined herein.


 


Also, the Analysis are based on
current economic and market conditions and, in case these vary in the future, they should be revised.


 


In light of the foregoing, neither
ALANTRA nor any of its subsidiaries, officers, directors, employees, auditors, counsels and other representatives accept any responsibility
whatsoever for damages or losses that, directly or indirectly, may derive from the decisions that are adopted based on the Analysis, nor
of the use that the recipients make of the Analysis except in the case of damages or losses resulting from ALANTRA’s gross misconduct
or gross negligence.


 


ALANTRA
acknowledges that, in connection with the Services to be provided pursuant to this letter agreement, certain confidential,
non-public and proprietary information concerning the Company, the Targets, any potential business combination and any potential
investors in connection therewith (“Company Confidential Information”) has been or may be directly or indirectly
disclosed by the Company, a Target or their respective Representatives to ALANTRA or its Representatives. ALANTRA agrees that,
without the Company’s prior consent, no Company Confidential Information will be (x) used by ALANTRA or its Representatives
other than in connection with performing the Services under this agreement or (y) disclosed, in whole or in part, by ALANTRA or its
Representatives to any other person other than: (i) to those Representatives of ALANTRA who need access to such Confidential
Information for purposes of performing the Services to be provided hereunder, who are informed of the confidential nature of such
information and bound by non-disclosure and non-use obligations consistent with the provisions of this agreement; (ii) to the
Company, its Board of Directors or executive officers and each of the Company’s other Representatives bound by confidentiality
obligations; or (iii) as may be required by applicable law, regulation, SEC or stock exchange requirement or legal process
(“Legal Requirement”). The term “Company Confidential Information” does not include any information:
(a) that was already in the possession of ALANTRA or any of its Representatives on a non-confidential basis prior to the time of
disclosure to ALANTRA or such Representatives; (b) obtained by ALANTRA or any of its Representatives from a third person which,
insofar as is known to ALANTRA or such Representatives after reasonably inquiry, is not subject to any prohibition against
disclosure; (c) which was or is independently developed by ALANTRA or any of its Representatives without use of or reference to any
Confidential Information or violating any confidentiality obligations under this agreement; or (d) which was or becomes generally
available to the public through no fault of or breach of this agreement by ALANTRA or its Representatives. If ALANTRA or its
Representative becomes required by Legal Requirement to disclose any Confidential Information, (x) ALANTRA shall provide prompt
notice thereof (to the extent permitted by Legal Requirement) to the Company reasonably in advance of any disclosure, (y) ALANTRA
will (and will cause its Representatives to) reasonably cooperate (at the sole expense of the Company) with any reasonable request
of the Company to seek an order or other remedy to prevent or narrow such disclosure, and (z) if after compliance with clauses (x)
and (y) above, such disclosure is still required after giving effect to any successful efforts by the Company to prevent or narrow
such disclosure, ALANTRA or its Representative, as applicable, may disclose only that Confidential Information which its counsel
advises it is required by Legal Requirement to disclose. For purposes of this letter agreement, the term
“Representatives” with respect to any person shall mean such person’s affiliates and its and its affiliate’s
respective directors, managers, officers, employees, consultants, shareholders, advisors, appraisers, agents and other
representatives.


 







    5/10


     


    

 





 


ALANTRA acknowledges that U.S.
securities laws and other laws prohibit any person who has material, non-public information concerning a public company from purchasing
or selling any of its securities, and from communicating such information to any person under circumstances in which it is reasonably
foreseeable that such person is likely to purchase or sell such securities. ALANTRA acknowledges that the confidentiality provisions of
this Section 4 shall be deemed to be an agreement to keep the Company Confidential Information in confidence as contemplated by Regulation
FD promulgated by the SEC. In addition, ALANTRA acknowledges and agrees that some of the Company Confidential Information (including the
fact that discussions between the Company and any Target have been undertaken with respect to a Transaction) may be considered “material
non-public information” for purposes of the federal securities laws and that ALANTRA and its Representatives will abide by all securities
laws relating to the handling of and acting upon material non-public information of the Company.


 


Any advice or opinions provided
by ALANTRA may not be disclosed or referred to publicly or to any third party except in accordance with our prior written consent, except
when required to be disclosed by any supervisory body or authority or by law or regulations. The Company agrees to keep confidential the
terms of this engagement.


 


The Company acknowledges and agrees
that ALANTRA may describe or refer to ALANTRA’s involvement in any Transaction resulting from its engagement under this letter agreement
and its services rendered in any advertisements placed in financial or other newspapers and journals (at ALANTRA’s expense) and
in any pitch, presentation or other such similar marketing materials which ALANTRA uses as part of its ordinary course of financial advisory
services, in the web page of the Alantra Group or in its annual reports provided that (i) the intended Transactions are completed, (ii)
the Transaction becomes public other than as a result of ALANTRA’s disclose.


 


The obligations of ALANTRA set
forth in this Section 4 shall remain in effect during the term of two (2) years from the date hereof.


 


5. Full Services Firm


 


Please note that Alantra Group
is engaged in asset management and securities trading and brokerage, as well as providing capital markets and financial advisory services.
As required by applicable laws, regulations and necessary and appropriate internal policies, the Alantra Group has in place "Chinese
wall" procedures generally separating sales, trading and asset management areas of the firm from financial advisory. Accordingly,
in the ordinary course of Alantra Group’s trading, brokerage, financing services and asset management, the Alantra Group may at
any time manage, hold long or short positions, and may trade or otherwise effect transactions, for their own account or the accounts of
customers, in debt or equity securities or loans of any company that may be involved in the Transaction. It is further agreed that, to
the fullest extent permitted by law, this engagement and the transactions contemplated hereunder do not give rise to any duties (including,
without limitation, fiduciary, equitable, or contractual) which would preclude or limit in any way the ability of the Alantra Group to
provide similar services to other customers, or otherwise to act on behalf of other customers, in relation to matters not directly related
to this engagement or the transactions
hereunder. The Company hereby acknowledges and agrees that, by reason of law or duties of confidentiality owed to other persons
or the rules of any regulatory authority, the Alantra Group may be prohibited from disclosing information to you (or such disclosure may
be inappropriate), including information as to the Alantra Group’s possible interests as described in this paragraph and information
received pursuant to client relationships.


 




    6/10


     


    

 





 


6. Delegation and agents


 


The Company agrees that ALANTRA,
after written approval by the Company which not be unreasonably withheld may appoint one or more of its subsidiaries or affiliates or
such other person or persons as ALANTRA thinks fit to act as agent, delegate, sub-contractor or otherwise in connection with or pursuant
to the Transactions and also agrees that we may authorise such persons to further sub-delegate their appointment. This power of delegation
shall be without prejudice to ALANTRA’s responsibility to the Company for the fulfilment of ALANTRA’s obligations. References
in this letter agreement to “ALANTRA”, “we” and “us” shall, save where the context otherwise requires,
include any such subsidiaries, affiliates, agents, delegates or subcontractors.


 


7. Term and Termination


 


This engagement come in full force
and effect on the date of signature by both the Company and ALANTRA and may be terminated by the Company or by ALANTRA at any time with
or without cause upon 15 days written notice and without any liability or continuing obligation to you or to us (a “Convenience
Termination”); or by providing written notice to the other party in the event of gross negligence or gross misconduct by the other
party and failure of that party to cure the consequences of such gross negligence or gross misconduct within 10 days after receipt of
the notice (a “Cause Termination”); provided that, Section 4 (Information and Confidentiality), Section 9 (Liability
and Indemnification), Section 11 (Applicable Law and Jurisdiction), Section 13 (Waiver Against Trust) will remain in full force and effect
regardless of any such termination.


 


 


ALANTRA will be entitled to receive
the Transaction Success Fee while this letter agreement is in force or in the case of a Convenience Termination by the Company or a Cause
Termination by ALANTRA, within 12 months of the date of termination of this letter agreement , if you or any of your affiliates effectuates
(wholly or substantially) the Transaction contemplated by this letter agreement or any other Transaction(s) having in all material respects
a similar effect. For the avoidance of doubt, in the event of a Convenience Termination by ALANTRA or a Cause Termination by the Company,
ALANTRA shall not be entitled to any Transaction Success Fee after termination. No termination or expiration of this letter agreement
or ALANTRA’s engagement hereunder shall affect the Company’s obligation to reimburse ALANTRA for its accrued expenses incurred
in performance of the Services prior to such termination.


 


8. Exclusivity


 


While this agreement is in force,
you undertake not to entrust to other advisors similar undertakings relating to the Services described in this letter agreement in Europe,
Latin America and the Middle East.


 




    7/10


     


    

 





 


9. Liability and indemnification


 


Subject to Section 13, the Company
agrees to indemnify and hold harmless ALANTRA and its directors, officers, agents, employees, affiliates and controlling parties (each
a “Indemnified Party”) from and against any and all losses, claims, damages or liabilities (or actions in respect thereof)
relating to the performance by ALANTRA of the Services contemplated by this letter agreement and will reimburse any Indemnified Party
for all expenses (including reasonable legal fees and expenses) as they are incurred in connection with investigating, preparing or defending
any such action or claim, except where a court of competent jurisdiction has rendered a final judgment that such action or claim resulted
from ALANTRA’s wilful misconduct or gross negligence.


 


ALANTRA will only be liable (whether
directly or indirectly, in contract or tort or otherwise) to the Company and any of its affiliates in connection with the Transaction
when a court of competent jurisdiction has rendered a final judgment that such action or claim resulted from ALANTRA wilful misconduct
or gross negligence. The parties agree to limit the liability of ALANTRA when it has acted with gross negligence or wilful misconduct
up to the amount of the fees paid by the Company in accordance with this document. This limitation of responsibility is the result of
the negotiations held by the parties, whereby the amount of the fees to be received by ALANTRA has been agreed taking into account the
maximum amount which may be claimed to ALANTRA in connection with its liability hereunder. Any responsibility on the side of the ALANTRA
shall be assumed by ALANTRA and, accordingly, any responsibility of its group companies and its board members, directors or employees,
is hereby expressly assumed by ALANTRA.


 


Client agrees that ALANTRA cannot
be held liable or deemed in default under the present letter agreement for any breach of an obligation arising hereunder, when such failure
is solely the responsibility of a third party, which is not under the control of ALANTRA. In addition, ALANTRA’s liability cannot
be increased by any agreement made by the Company, with a third party, without the consent of ALANTRA, that limits the liability of that
third party.


 


10. Data Protection


 


The Company
is hereby informed and expressly consents, by signing this agreement, to the processing of the personal data voluntarily provided in
the course of the Transaction, as well as of any data which might be provided to ALANTRA, directly or indirectly, for the enforcement
of this agreement or regarding the contracting of any service or product, even after the end of the contractual relation, including,
if applicable, any communication or international data transfer among members of the Alantra Group which might be made for the purposes
specified in our Data Protection Policy1 (the “Data Protection Policy”).


 


Where
you provide personal data on behalf of another individual, you are responsible for notifying that individual that you have provided
their personal data to us and directing them to our Data Protection Policy so they can see how we will process their personal data .
The Company guarantees the accuracy and truthfulness of the personal data provided, undertaking to keep them duly updated and to
notify to ALANTRA of any changes.


 


	1	https://www.alantra.com/data-protection-policy/



 




    8/10


     


    

 





 


By executing this agreement, the
Company accepts the processing and communication of its personal data by ALANTRA for the delivery of information and advertising on the
Alantra Group products and services. In any case, your consent to the treatment of your data for these purposes is revocable, and you
may withdraw your consent or exercise any of the rights mentioned in our Data Protection Policy.


 


11. Applicable law and jurisdiction


 


This agreement shall be governed
by and construed in accordance with the laws of the United Kingdom. The parties irrevocably agree that the Courts of London, United Kingdom,
have the exclusive jurisdiction to settle any disputes which may arise out of or in connection with this letter and that accordingly any
suit, action or proceeding arising out of or in connection with this letter may be brought in such courts.


 


12. Waiver Against Trust


 


Reference
is made to the final prospectus of The Company, dated as of April 27, 2022 and filed with the Securities and Exchange Commission
(File No. 333- 263542) on April 29, 2022 (the “Prospectus”). ALANTRA understands that The Company has established
a trust account (the “Trust Account” ) containing the proceeds of its initial public offering (the “ IPO”
) and the overallotment securities acquired by its underwriters and from certain private placements occurring simultaneously with
the IPO (including interest accrued from time to time thereon) for the benefit of the Company’ s public stockholders
(including overallotment shares acquired by the Company’s underwriters), and that, the Company may disburse monies from the
Trust Account only as described in the Prospectus, its organizational documents or the Investment Management Trust Agreement entered
into in connection with the IPO. For and in consideration of the Company entering into this letter agreement, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ALANTRA hereby agrees on behalf of itself and
its affiliates that, notwithstanding anything to the contrary in this letter agreement, neither ALANTRA nor any of its affiliates do
now or shall at any time hereafter have any right, title, interest or claim of any kind in or to any monies in the Trust Account or
distributions therefrom, or make any claim against the Trust Account (including any distributions therefrom), regardless of whether
such claim arises as a result of, in connection with or relating in any way to, this letter agreement or any proposed or actual
business relationship between the Company or its Representatives, on the one hand, and ALANTRA or its Representatives, on the other
hand, or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other theory of legal
liability (collectively, the “Released Claims”). ALANTRA on behalf of itself and its affiliates hereby
irrevocably waives any Released Claims that ALANTRA or any of its affiliates may have against the Trust Account (including any
distributions therefrom) now or in the future as a result of, or arising out of, this letter agreement and will not seek recourse
against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for an alleged breach of this
Letter agreement or any other agreement with the Company or its affiliates). ALANTRA agrees and acknowledges that such irrevocable
waiver is material to this letter agreement and specifically relied upon by the Company and its affiliates to induce the Company to
enter in this letter agreement, and ALANTRA further intends and understands such waiver to be valid, binding and enforceable against
ALANTRA and each of its affiliates under applicable law. The provisions of this Section 13 shall survive any expiration or
termination of this letter agreement and continue indefinitely.


 




    9/10


     


    

 





 


13. General


 


This letter agreement represents
the entire agreement between the Company and ALANTRA with respect to this engagement and may only be amended in writing. Each provision
of this letter agreement is severable and if any such provision is or becomes invalid or illegal or unenforceable, the remaining provisions
will not be affected.


 


This letter agreement may be executed
in any number of counterparts, each of which when executed and delivered shall constitute an original of this letter agreement, but all
the counterparts shall together constitute the same agreement.


 


Should the terms and conditions
of the present agreement become acceptable to you, please sign and return the copy enclosed.


 


Before signing this document,
please read the basic data protection information given in the Data Protection clause. By signing this document, you c onsent to the processing
of your personal data in the terms and conditions stipulated in such clause.


 


In this letter agreement, the
term: (i) “including” (and with correlative meaning “include”) shall be deemed in each case to be followed by
the words “without limitation”; (ii) “person” shall refer to any individual, corporation, partnership, trust,
limited liability company or other entity or association, including any governmental or regulatory body, whether acting in an individual,
fiduciary or any other capacity; and (iii) “affiliate” shall mean, with respect to any specified person, any other person
or group of persons acting together that, directly or indirectly, through one or more intermediaries controls, is controlled by or is
under common control with such specified person (where the term “control” (and any correlative terms) means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership
of voting securities, by contract or otherwise). For the avoidance of doubt, any reference in this letter agreement to an affiliate of
the Company prior to the closing of a business combination will include its sponsor, U.N. SDG Support LLC.


 


Yours sincerely,


 


Alantra Corporate Finance,
S.A.


 


	/s/ Miguel Hernandez Maestro	 	/s/ Cesar Ciriza Santero
	Miguel Hernández Maestro	 	César Ciriza Santero



 


	 	Agreed and
accepted,
	 	 
	 	ClimateRock
	 	 
	 	/s/ Per Regnarsson
	 	Per Regnarsson



 


 


10/10